The United Kingdom will offer weight loss injections to the overweight unemployed in order to improve the national economy

This article was originally published in English

The secretary of Health Brit, Wes Streeting, has revealed plans to administer slimming injections to the unemployed diagnosed with obesity, with the aim of helping them rejoin the labor market and boost the UK economy. The distribution of these slimming drugs will be part of a £280 million investment in the United Kingdom by Lilly, the world’s largest pharmaceutical company and manufacturer of the slimming drug. Mounjaro.

As part of the investment, Lilly will carry out the first test in real conditions of the effect of drugs on the unemployed, the productivity and dependence on the NHS. Currently, Mounjaro is only used for treat weight loss and the diabetes type 2. There is still no empirical data on its effectiveness in non-clinical outcomes, such as this one related to economics.

The increase in waistlines slows down our economy

Streeting believes the new class of drugs could have a “monumental” impact on obesity and get the UK “up and running”. In an article published in the Daily Telegraph, he painted a bleak picture of the country’s health: “As a country, we eat morewe eat less healthy and we do less exercise. “The cost to the individual is obvious: a less healthy and shorter life.”

“In addition, the increase in the waist represents an important burden on the health system, at a cost of 11 billion pounds (13 billion euros) a year, including more than tobacco. And it is holding back our economy. Diseases caused by obesity cause people to take an average of four more days a year due to illnesswhile many others are forced to stop working.

The magnitude of the challenge is enormous

According to a British Government spokesperson, obesity is the second preventable cause of cancer and one of the main factors of poor health that prevent people from participating fully at work. The British Government’s collaboration with big pharma is expected to announce a new era of technological advances that improve the long-term health of those suffering from obesity.

In the words of a Government spokesperson: “Despite all the challenges facing the health of our nation, we have two great advantages: some of the world’s leading scientific minds and a National Health Service with enormous potential. If we are able to combine both, patients in this country will be able to reap the fruits of the revolution in medical science that is unfolding before our eyes.”

Demonstrating the effectiveness of fat injections is crucial

The success of Mounjaro’s trials, known as the ‘King Kong’ of weight loss injections for being the most effective on the marketis vital to Streeting’s plan to put the obese back into work. The metropolitan area of Manchester has been chosen as the venue for the first rehearsal. Figures suggest obesity currently costs £3.2bn (€3.8bn) to the economy, around half of which is lost productivity.

Greater Manchester Mayor Andy Burnham said: “The trial results announced today could have a powerful impact in the way we address obesity on a global scale, and our city-region is poised to make a significant contribution through our exceptional health assets. health dataour R&D expertise and strong partnerships between industry, universities and public sector organisations.”